Aurinia Pharmaceuticals Inc. AUPH
Institutional shares held
69.3 Million
984K
calls
574K
puts
Total value of holdings
$1.06B
$15.1M
calls
$8.8M
puts
Market Cap
$2.18B
141,892,000
Shares Out.
Institutional ownership
48.85%
# of Institutions
268
We take great care to ensure that the data presented and summarized in this overview for Aurinia Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AUPH
View all-
Tang Capital Management LLC San Diego, CA11.3MShares$174 Million5.69% of portfolio
-
Black Rock Inc. New York, NY9.27MShares$142 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$60.9 Million2.74% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.37MShares$51.8 Million0.03% of portfolio
-
State Street Corp Boston, MA2.69MShares$41.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.95MShares$29.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.56MShares$23.9 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.49MShares$22.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.49MShares$22.8 Million0.0% of portfolio
-
Marshall Wace, LLP London, X01.48MShares$22.8 Million0.02% of portfolio
Latest Institutional Activity in AUPH
Top Purchases
Top Sells
About AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Transactions at AUPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2026
|
Peter Greenleaf Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
113,169
-5.78%
|
$1,697,535
$15.95 P/Share
|
|
Jan 02
2026
|
Peter Greenleaf Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,384
+7.8%
|
-
|
|
Jan 02
2026
|
Joseph M Miller Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
40,161
-6.38%
|
$602,415
$15.95 P/Share
|
|
Jan 02
2026
|
Joseph M Miller Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,038
+7.26%
|
-
|
|
Jan 02
2026
|
Matthew Maxwell Donley Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,787
-5.79%
|
$641,805
$15.95 P/Share
|
|
Jan 02
2026
|
Matthew Maxwell Donley Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,166
+6.87%
|
-
|
|
Jan 02
2026
|
Stephen P. Robertson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
40,385
-7.23%
|
$605,775
$15.95 P/Share
|
|
Jan 02
2026
|
Stephen P. Robertson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
48,558
+8.01%
|
-
|
|
Nov 21
2025
|
Craig A Johnson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,039
-29.27%
|
$90,585
$15.68 P/Share
|
|
Nov 21
2025
|
Jeffrey Allen Bailey Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,716
-10.65%
|
$40,740
$15.68 P/Share
|
|
Aug 05
2025
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
200,000
+1.73%
|
$2,200,000
$11.68 P/Share
|
|
Aug 04
2025
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.89%
|
$1,100,000
$11.34 P/Share
|
|
Aug 01
2025
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+8.31%
|
$10,000,000
$10.12 P/Share
|
|
Aug 01
2025
|
Greg Keenan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-13.03%
|
$200,000
$10.5 P/Share
|
|
Mar 07
2025
|
Greg Keenan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,305
-5.13%
|
$66,440
$8.23 P/Share
|
|
Mar 04
2025
|
Peter Greenleaf Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
164,947
-8.44%
|
$1,154,629
$7.92 P/Share
|
|
Mar 04
2025
|
Matthew Maxwell Donley Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
58,991
-7.98%
|
$412,937
$7.92 P/Share
|
|
Mar 04
2025
|
Stephen P. Robertson EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
57,607
-10.16%
|
$403,249
$7.92 P/Share
|
|
Mar 04
2025
|
Joseph M Miller Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
56,154
-8.86%
|
$393,078
$7.92 P/Share
|
|
Mar 04
2025
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
748,038
+2.44%
|
$5,984,304
$8.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
4.51M
Shares
From
6
Insiders
| Open market or private purchase | 2.9M shares |
|---|---|
| Grant, award, or other acquisition | 1.61M shares |
Sell / Disposition
1.01M
Shares
From
11
Insiders
| Payment of exercise price or tax liability | 245K shares |
|---|---|
| Open market or private sale | 766K shares |